AstraZeneca PLC (AZN)vsLockheed Martin Corporation (LMT)
AZN
AstraZeneca PLC
$185.78
+0.93%
HEALTHCARE · Cap: $284.63B
LMT
Lockheed Martin Corporation
$624.20
+2.30%
INDUSTRIALS · Cap: $144.44B
Smart Verdict
WallStSmart Research — data-driven comparison
Lockheed Martin Corporation generates 28% more annual revenue ($75.05B vs $58.74B). AZN leads profitability with a 17.4% profit margin vs 6.7%. LMT appears more attractively valued with a PEG of 1.34. AZN earns a higher WallStSmart Score of 66/100 (B-).
AZN
Strong Buy66
out of 100
Grade: B-
LMT
Buy65
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+32.8%
Fair Value
$306.07
Current Price
$185.78
$120.29 discount
Margin of Safety
+37.5%
Fair Value
$1005.26
Current Price
$624.20
$381.06 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Earnings expanding 53.9% YoY
Every $100 of equity generates 23 in profit
Strong operational efficiency at 21.6%
Generating 1.4B in free cash flow
Every $100 of equity generates 77 in profit
Large-cap with strong market position
Generating 2.8B in free cash flow
Areas to Watch
Moderate valuation
4.1% revenue growth
Distress zone — elevated risk
Moderate valuation
1.6% earnings growth
6.7% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, EPS Growth, Return on Equity. Profitability is solid with margins at 17.4% and operating margin at 21.6%.
Bull Case : LMT
The strongest argument for LMT centers on Return on Equity, Market Cap, Free Cash Flow. PEG of 1.34 suggests the stock is reasonably priced for its growth.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Revenue Growth, Altman Z-Score.
Bear Case : LMT
The primary concerns for LMT are P/E Ratio, EPS Growth, Profit Margin. Debt-to-equity of 3.23 is elevated, increasing financial risk.
Key Dynamics to Monitor
AZN carries more volatility with a beta of 0.23 — expect wider price swings.
LMT is growing revenue faster at 9.1% — sustainability is the question.
LMT generates stronger free cash flow (2.8B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
AZN scores higher overall (66/100 vs 65/100), backed by strong 17.4% margins. LMT offers better value entry with a 37.5% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Lockheed Martin Corporation
INDUSTRIALS · AEROSPACE & DEFENSE · USA
Lockheed Martin Corporation is an American aerospace, defense, information security, and technology company with worldwide interests. It is headquartered in North Bethesda, Maryland, in the Washington, D.C., area.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?